STING1 and neoplasm: Furthermore, compared with the use of exogenous agonizts to activate the STING pathway, our approach provides a simple and effective approach to utilize the abundant tumor DNA to activate the STING pathway in situ and therefore can bypass the limited tumor-targeted delivery of exogenous STING agonists.